#### Tetrahedron 68 (2012) 7140-7147

Contents lists available at SciVerse ScienceDirect

## Tetrahedron



## Stereoselective photoinduced electrocyclic ring closure of aromatic enehydrazides. Asymmetric synthesis of 3-aryl dihydroisoquinolones and tetrahydroisoquinolines

Mélanie Dubois<sup>a,b</sup>, Eric Deniau<sup>a,b</sup>, Axel Couture<sup>a,c,\*</sup>, Pierre Grandclaudon<sup>a,b</sup>

<sup>a</sup> Univ Lille Nord de France, F-59000 Lille, France

<sup>b</sup> USTL, Laboratoire de Chimie Organique Physique, EA CMF 4478, Bâtiment C3(2), F-59655 Villeneuve d'Ascq Cedex, France <sup>c</sup> CNRS, UMR 8181 'UCCS', Bâtiment C3(2), F-59655 Villeneuve d'Ascq Cedex, France

#### ARTICLE INFO

Article history: Received 23 March 2012 Received in revised form 6 June 2012 Accepted 8 June 2012 Available online 15 June 2012

Keywords: Asymmetric synthesis Enol phosphates Cross-coupling Chiral enehydrazides Photocyclization 3-Arylisoquinolones

#### 1. Introduction

The isoquinoline core is one of Nature's most popular structural motif and this ring system lies at the heart of a large number of natural and synthetic bioactive compounds.<sup>1</sup> In particular those in which the azaheterocycle unit is partially hydrogenated occupy a noticeable place in this class of interesting alkaloids because of their manifold pharmacological properties, e.g., fibrinolytic, antiviral, tranquilizing, muscle relaxant, hypotensive and positive inotropic effects.<sup>1,2</sup> Isoquinolinones are somewhat less prominent but very often they serve a key role as advanced intermediates prior to their conversion to isoquinolines. Consequently the development of general methodologies leading to molecular diversity in a highly efficient stereo and enantioselective manner is a permanent challenging task for organic chemists and interest in this field continues unabated.<sup>3–5</sup> While much effort has been devoted to the asymmetric synthesis of 1-substituted models,<sup>5m,6</sup> the stereoselective elaboration of 3-substituted dihydroisoquinolones and tetrahydroisoquinolines has much less precedent in the literature.

### ABSTRACT

A flexible route for the stereoselective synthesis of a variety of 3-aryl dihydroisoquinolones and tetrahydroisoquinolines has been developed. The key step is a diastereoselective photoinduced  $6\pi$ -electrocyclic ring closure of enantiopure aromatic enehydrazides via a 1,4-remote asymmetric induction. N–N bond cleavage to release the chiral appendage from the preliminary annulated compounds and/or concomitant reduction of the lactam carbonyl group completed the synthesis of the title compounds. © 2012 Elsevier Ltd. All rights reserved.

> The 3-arylated models fall into this category and are of particular interest since they are known as a relevant class of compounds among the isoquinoline alkaloids.<sup>1</sup> They can be regarded as important synthetic intermediates for the construction of structurally related alkaloids like protoberberines, e.g., xylopinine, pavines, e.g., (–)-argemonine, and benzo[*c*]phenanthridines, e.g., chelerythrine (Fig. 1).<sup>1,7</sup> They are also enjoying considerable attention as potential therapeutic agents<sup>8</sup> as evinced by bombesin-2 (BB2) receptor antagonist<sup>9</sup> and MDM2-p53 interaction inhibitors<sup>10</sup> (Fig. 1).

> The asymmetric synthetic methods for the elaboration of 3-arylated dihydroisoquinolones can be cursorily classified into three main categories whose fundamental tenets come within the scope of the lateral metalation methodology pioneered by Clark et al.<sup>11</sup> (Scheme 1). The first one hinges upon a tandem addition/ cyclization of lithiated 2-methylbenzamides to imine appended chiral auxiliary, such as sulfinyl imines developed by Davies<sup>5b,e,1,12</sup> and Chrzanowska<sup>4a,b</sup> (path 1a) or SAMP hydrazones exploited by Enders<sup>13</sup> (path 1b). For the second one (path 2) enantioinduction is secured by making use of achiral imines and laterally lithiated (*S*) or (*R*)-o-toluamides equipped with a chiral auxiliary derived from (*S*) or (*R*)-phenylalaninol. At last the same synthetic approach was skillfully developed by Snieckus<sup>5a</sup> and Liu<sup>4c</sup> starting from achiral substrates and enantioinduction was achieved this time via addition of the chiral ligand (–)-sparteine (path 3). It is also worth noting that





<sup>\*</sup> Corresponding author. Tel.: +33 (0) 3 20 43 44 32; fax: +33 (0) 3 20 33 63 09; e-mail address: axel.couture@univ-lille1.fr (A. Couture).

<sup>0040-4020/\$ –</sup> see front matter @ 2012 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.tet.2012.06.037



**Fig. 1.** Natural and synthetic bioactive compounds incorporating the 3-arylisoquinoline or isoquinolone skeleton.

a stereocontrolled synthesis of 3-aryltetrahydroisoquinoline by a Pictet–Spengler heterocyclization reaction of optically active 1,2diarylethylamines has been developed but the resulting compounds were invariably alkylated at the C1 position.<sup>5</sup> The same unsubstituted models could also be obtained by deoxygenation of isoquinolinols prepared from chiral arylglycines under ionic hydrogenation conditions.<sup>4d</sup> All these methods are generally efficient and of procedural simplicity but they have also been claimed to proceed with varying degrees of success with regard to their enantioselectivities. Consequently the development of alternative and efficient methodologies, which may find generality for constructing polyhydroisoquinolones and isoquinolines with aryl appendage at C3 in a stereoselective manner is currently the object of synthetic endeavor.<sup>4,13</sup>



Path 3  $X = CONEt_2$  Y = R, (-)-sparteine added Scheme 1. Synthetic strategies for the stereoselective synthesis of 3-arylated dihvdroisoouinolones.

In this paper we wish to delineate a novel route to a variety of diversely substituted 3-aryl polyhydroisoquinolones and quinolines, **1** and **2**, respectively, that is based upon the use of chiral aromatic enehydrazides **3** as substrates for photoinduced ring closure to secure the formation of the lactam unit, that is ring B in the title compounds (Scheme 2). Ensuing deprotection by N–N cleavage of the hydrazide bond of the preliminary annulated compounds**4** possibly associated with reduction of the carbonyl function then should provide an entry to the targeted optically active compounds **1**,**2**.



Scheme 2. Retrosynthetic analysis.

The photocyclization of enamides has been developed as an efficient synthetic route toward six-membered azaheterocycles and a wide range of alkaloids has been synthesized in this way.<sup>14</sup> Under oxidative, non oxidative and reductive conditions enamides **A** undergo smooth photochemical cyclization via a common intermediate **B** (Scheme 3) and the formation of the lactam unit at different oxidation levels can be rationalized by loss of hydrogen, [1,5]-hydrogen shift or hydride fixation, respectively.



**Scheme 3.** Photochemical behavior of enamides upon irradiation under various conditions.

Although a number of possibilities exist for inducing stereoselectivities in photochemical reactions<sup>15</sup> little attention has been paid to the development of photocyclization processes that could ensure the control of the stereogenic center  $\alpha$  to the nitrogen atom, a challenging task in alkaloid total synthesis. In a few early reports reductive photocyclization of enamides was carried out in the presence of chiral metal hydride complex (Scheme 3) but both the chemical yields and enantioselectivities were rather modest.<sup>16</sup> Methodologies based upon the photoinduced cyclization of chiral aromatic enamides are rather scarce. These photochemical studies have been indeed confined to aliphatic dienamides<sup>17</sup> and to structurally sophisticated models that require additional tedious chemical transformation to access the targeted compounds,<sup>18</sup> both with moderate selectivities.

#### 2. Results and discussion

Our new synthetic approach hinges upon the photoinduced cyclization of aromatic enehydrazides **3** equipped with a temporary activating auxiliary issued from the chiral pool, that is (S)-O-methvlprolinol (Scheme 2). We speculated that upon photoinduced ring closure under anaerobic conditions, the presence of this rather bulky appendage could have a marked impact on the [1,5]-H shift from intermediate structurally related to B and then force and favor the privileged formation of diastereomerically enriched annulated models 4. The first facet of the synthesis, which is depicted in Scheme 4 was then the elaboration of the enehydrazides **3**. The construction of these unsaturated compounds revealed to be more problematic that we had anticipated. All attempts to access the desired precursors following the classical method usually employed for the synthesis of styrenic enamides,<sup>19</sup> that is base-induced treatment of hydrazones **5** issued from the condensation of suitable benzophenones 6 and (S)aminomethoxymethylpyrrolidine (SAMP), with an appropriate acid chloride 7 met with no success, probably due to competing acylation sites. We then set out to achieve an alternative strategy to secure the creation of the styrene unit tailed to the aromatic hydrazide moiety. We surmised that the acetylated hydrazides 8 would possess the appropriate functionalities required for the installation of the

mandatory styrene unit through a palladium-mediated cross-coupling reaction. Since the pioneering work of Oshima et al.<sup>20</sup> several group have successfully and elegantly used constitutionally diverse enol phosphates in a variety of Pd(PPh<sub>3</sub>)<sub>4</sub> catalyzed cross-coupling reaction.<sup>21</sup> It has been notably demonstrated that enol phosphates deriving from *N*-alkylamides are effective substrates for such coupling reaction provided that the model compounds are further equipped with electron withdrawing groups on nitrogen atom. Despite the fact that to the best of our knowledge such studies have not been performed with N-substituted hydrazides we were reasonably optimistic about the chances of success for this approach since the diacylated hydrazines 8 fulfill these stringent structural criterions. Initially the benzoyl chlorides **7a**,**b** were efficiently converted into the corresponding hydrazides (S)-9a,b under standard conditions. Deprotonation of (S)-9a,b with NaH in THF and subsequent capture of the transient sodium salt with acetyl chloride delivered guite satisfactory yields of the chiral *N*-acetylated hydrazides (*S*)-**8a,b**. With rapid access to these diacylated models the focus of the research shifted to the use of these compounds as advanced intermediates for the concise and efficient conversion of the acetyl moiety into a styrene unit.

We were then pleased to observe that exposure of compounds (*S*)-**8a,b** to KHMDS in THF at -78 °C provided a potassium enolate, which was intercepted with diphenyl chlorophosphate to afford the sensitive vinyl phosphate **10**. Subsequent Pd-catalyzed Suzu-ki–Miyaura coupling reaction was then applied under well defined conditions. The vinyl phosphate thus obtained **10**, a suitably aromatic boronic acid **11a**–**e**, Pd(PPh<sub>3</sub>)<sub>4</sub> as the catalyst, aqueous Na<sub>2</sub>CO<sub>3</sub> (2 M), a few drops of EtOH were refluxed in THF. Under these conditions the expected enantiopure styrene hydrazides (*S*)-**3a**–**f**, candidates for the planned photoinduced ring closure, were isolated in very satisfactory yields (Scheme 4, Table 1). As far as we



Table 1 Compounds **3a**–**f**, **4a**–**f**, **1a**–**f** and **2a**,**d**,**e** prepared

_														
		$\mathbb{R}^1$		R <sup>2</sup>	R <sup>3</sup>	$\mathbb{R}^4$								
	8a	Н	11a	Н	Н	Н	8a+11a→3a	65%	4a	68%	1a	75%	2a	63%
	8a	Н	11b	OMe	OMe	Н	$8a{+}11b{\rightarrow}3b$	70%	4b	63%	1b	70%	—	_
	8a	Н	11c	OMe	OMe	OMe	$8a+11c \rightarrow 3c$	58%	4c	67%	1c	74%	—	—
	8a	Н	11d	Н	OMe	Н	$8a{+}11d{\rightarrow}3d$	62%	4d	62%	1d	72%	2d	68%
	8a	Н	11e	OCH <sub>2</sub>	0	Н	$8a+11e \rightarrow 3e$	68%	4e	65%	1e	73%	2e	58%
	8b	OMe	11b	OMe	OMe	Н	$8b{+}11b\!\rightarrow\!3f$	55%	4f	61%	1f	67%	—	_

are aware such reactions performed in the hydrazide series are unprecedented and should be of interest for alternative synthetic planning. For the crucial photocyclization process a carefully degassed methanolic solution of chiral enehydrazides (S)-3a-f (4  $10^{-3}$  M;  $\lambda_{max}$ =205, 260, 300 nm) was placed in a quartz vessel and irradiated under Ar in a Rayonet RPR photoreactor equipped with eight 254 nm lamps for 4 h. Subsequent removal of the solvent and flash column chromatography delivered very satisfactory vields of the requisite annulated (S,S)-4a-f (Scheme 5, Table 1). To our delight these lactamic compounds were obtained essentially as single diastereomers detectable by NMR (de >98% after chromatographic treatment)<sup>22</sup> making evident the high selectivity of the initial diastereofacial [1,5]-hydrogen shift process allowing introduction of the absolute stereochemistry at the newly created benzylic carbon center. From a mechanistic point of view one can tentatively assume that the chiral auxiliary is blocking the lower face of the plane of the hexatriene mesomeric form of (S)-3a-f. Upon the  $6\pi$ -electrocyclization process the two terminal vinyl and aromatic strands rotate in a conrotatory manner away from the pendant methoxymethyl group of the pyrrolidine auxiliary, which may sterically interacts with the styrene unit (Scheme 5). The suprafacial [1,5]-H shift from the transient hydrazinium species then occurs exclusively on the less hindered diastereotopic face and this highly diastereoselective electrocyclization is actually achieved via an unusual 1,4-remote asymmetric induction. These results are in good agreement with the stereoselective  $6\pi$ -electron cyclic ring closure of structurally related amidotrienes.<sup>23</sup> Ultimate treatment of (*S*,*S*)-**4a**-**f** with magnesium monoperoxyphthalate (MMPP)<sup>24</sup> triggered off the exclusive cleavage of the chiral appendage and this operation delivered very satisfactory yields of the virtually enantiopure 3-aryl-1(2*H*)-dihydroisoquinolones (*S*)-**1a**-**f** (Scheme 5, Table 1).

Finally treatment with the borane/THF complex of (*S*,*S*)-**4a**–**f** followed by aqueous alkaline work up effected reductive N–N bond cleavage with the concomitant reduction of the lactam carbonyl group to afford the targeted 3-aryltetrahydroisoquinolines (*S*)-**2a**,**d**,**e**. The absolute configuration of the newly created stereogenic center in **1** and **2** that was confirmed to be (*S*) as well as the enantiopurity of our synthetic compounds were clearly established from the sign and value of the optical rotation that matched those reported from authentic sample assembled by conceptually different synthetic approaches, e.g., {(*S*)-**1a**: mp 130–131 °C,  $[\alpha]_D^{20}$ –198.3 (*c* 0.97, CHCl<sub>3</sub>); lit.:<sup>5e</sup> mp 130–131 °C,  $[\alpha]_D^{20}$ –203.4 (*c* 1.03, CHCl<sub>3</sub>)} and {(*S*)-**2a**:  $[\alpha]_D^{20}$ –125.5 (*c* 0.48, CH<sub>2</sub>Cl<sub>2</sub>); lit.:<sup>25</sup> (*R*)-enantiomer  $[\alpha]_D^{20}$  +125.0 (*c* 0.55, CH<sub>2</sub>Cl<sub>2</sub>)}.

#### 3. Conclusion

In conclusion we have devised a new, convenient and flexible method for the enantioselective synthesis of 3-arylisoquinolones and isoquinolines. The key step is the highly diastereoselective photoinduced electrocyclization of enantiopure aromatic enehydrazides to generate the six-membered azaheterocyclic ring system via a 1,4-remote asymmetric induction. The main advantages of this synthetic approach lie in the small number of synthetic



Scheme 5. Synthesis and mechanistic rationalization for the enantioselective construction of 3-arylated isoquinolones and isoquinolines).

steps and the ready accessibility to the chiral SAMP hydrazides, which are easily assembled through a newly developed Suzuki–Miyaura cross-coupling reaction involving tailor-made enol phosphates. Owing to the availability of the RAMP chiral auxiliary we believe that this synthetic strategy should also allow for the construction of both antipodes of these 3-arylated isoquinolones and isoquinolines.

### 4. Experimental section

#### 4.1. General

Melting points were determined on a Reichert-Thermopan apparatus and are uncorrected. NMR spectra were recorded on Bruker AM 300 spectrometer and were referenced against internal TMS. IR spectra were recorded on a Nicolet 380 FT-IR spectrometer and UV spectra on a Shimadzu UV-2450 spectrometer. Optical rotations were measured with a Perkin Elmer 343 digital polarimeter at 589 nm. Enantiomeric excesses (ee >96%) were determined by HPLC analysis with a Chiracel OD column (hexane/2propanol, as eluent), UV detector 254 nm. Elemental analyses were obtained using a Carlo-Erba CHNS-11110 equipment. Flash chromatography was performed on Sorbent Technologies 32–63  $\mu m$  60 Å silica gel. Reactions were monitored by thin layer chromatography with Sorbent Technologies 0.20 mm silica gel 60 Å plates. Dry glassware was obtained by oven-drying and assembly under Ar and dry Ar was used as the inert atmosphere. The glassware was equipped with rubber septa and reagent transfer was performed by syringe techniques. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl immediately before use. Methanol was distilled over magnesium turning and CH<sub>2</sub>Cl<sub>2</sub> over CaH<sub>2</sub>.

#### 4.2. Hydrazides (S)-9a,b

Hydrazides (*S*)-**9a,b** were synthesized by following a previously reported procedure.<sup>26</sup>

4.2.1. *N*-((*S*)-2-*Methoxymethylpyrrolidin*-1-*y*l)*benzamide* [(*S*)-**9a**]. Recrystallization from hexane/toluene: colorless crystals, mp 156–157 °C,  $[\alpha]_{20}^{20}$  –27.3 (*c* 0.77, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3193, 1644, 1531 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =1.61–1.77 (m, 1H), 1.80–1.94 (m, 2H), 1.96–2.12 (m, 1H), 3.00 (q, *J*=8.5 Hz, 1H), 3.20–3.57 (m, 7H), 7.34–7.48 (m, 3H), 7.58 (br s, 1H), 7.72–7.85 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =21.3 (CH<sub>2</sub>), 26.4 (CH<sub>2</sub>), 55.4 (CH<sub>2</sub>), 59.2 (CH<sub>3</sub>), 64.5 (CH), 74.9 (CH<sub>2</sub>), 127.1 (2× CH), 128.6 (2× CH), 131.5 (CH), 133.8 (C), 166.5 (CO) ppm. Anal. Calcd for C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>: C, 66.64; H, 7.74; N, 11.96%. Found: C, 66.79; H, 7.70; N, 11.67%.

4.2.2. 4-Methoxy-N-((S)-2-methoxymethylpyrrolidin-1-yl)benzamide [(S)-**9b**]. Recrystallization from hexane/toluene: colorless crystals, mp 157–158 °C,  $[\alpha]_D^{20}$  –3.7 (*c* 1.39, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3190, 1636, 1537 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =1.60–1.78 (m, 2H), 1.84–1.96 (m, 2H), 1.98–2.15 (m, 1H), 2.95 (q, *J*=8.3 Hz, 1H), 3.17–3.30 (m, 1H), 3.34 (s, 3H), 3.39–3.58 (m, 2H), 3.84 (s, 3H), 6.91 (d, *J*=8.3 Hz, 2H), 7.12 (br s, 1H), 7.71 (d, *J*=8.3 Hz, 2H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =21.4 (CH<sub>2</sub>), 26.4 (CH<sub>2</sub>), 53.8 (CH<sub>2</sub>), 54.4 (CH<sub>3</sub>), 59.2 (CH<sub>3</sub>), 64.3 (CH), 75.3 (CH<sub>2</sub>), 114.3 (2× CH), 125.7 (C), 128.7 (2× CH), 159.9 (C), 162.4 (CO) ppm. Anal. Calcd for C<sub>14</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C, 63.62; H, 7.63; N, 10.60%. Found: C, 63.47; H, 7.87; N, 10.49%.

### 4.3. Acetylation of hydrazides (S)-9a,b. General procedure

A suspension of hydrazide (*S*)-**9a,b** (10 mmol) and NaH 60% (460 mg, 12 mmol) in THF (25 mL) was stirred at rt for 3 h under

Ar. Then a solution of acetyl chloride (942 mg, 12 mmol) in THF (5 mL) was added dropwise. The mixture was refluxed for 3 h. After cooling to rt water (10 mL) was added and the organic layer was separated. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×30 mL) and the combined organic layers were dried (MgSO<sub>4</sub>). Evaporation of the solvent furnished the crude acety-lated hydrazide **8a,b** as an oily product, which was purified by flash column chromatography using EtOAc/hexanes (10:90) as eluent.

4.3.1. *N*-Acetyl-*N*-((*S*)-2-methoxymethylpyrrolidin-1-yl)benzamide [(*S*)-**8a**]. Colorless oil,  $[\alpha]_{D}^{2D}$  -38.2 (*c* 1.73, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3191, 1686, 1644, 1533 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>, mixture of rotamers)  $\delta$  (major rotamer)=0.91–1.15 (m, 1H), 1.22–1.58 (m, 2H), 1.78–2.09 (m, 2H), 2.51 (s, 3H), 2.73–2.89 (m, 1H), 2.95–3.18 (m, 4H), 3.52–3.67 (m, 1H), 3.73–4.10 (m, 1H), 7.13–7.28 (m, 3H), 7.57–7.82 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>, mixture of rotamers):  $\delta$  (major rotamer)=20.2 (CH<sub>3</sub>), 23.6 (CH<sub>2</sub>), 28.2 (CH<sub>2</sub>), 52.5 (CH<sub>2</sub>), 58.2 (CH<sub>3</sub>), 61.6 (CH), 76.6 (CH<sub>2</sub>), 127.6 (2× CH), 128.1 (2× CH), 130.6 (CH), 137.6 (C), 172.6 (CO), 175.9 (CO) ppm. Anal. Calcd for C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C, 65.20; H, 7.30; N, 10.14%. Found: C, 65.03; H, 7.10; N, 10.05%.

4.3.2. *N*-Acetyl-4-methoxy-*N*-((*S*)-2-methoxymethylpyrrolidin-1-yl)benzamide [(*S*)-**8b**]. Colorless oil,  $[\alpha]_D^{20}$  –44.4 (*c* 1.63, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3188, 1688, 1662, 1540 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>, mixture of rotamers)  $\delta$  (major rotamer)=1.11–1.69 (m, 3H), 1.73–2.18 (m, 2H), 2.50 (s, 3H), 2.70–3.42 (m, 3H), 3.11 (s, 3H), 3.33 (s, 3H), 3.79–4.15 (m, 1H), 6.79 (d, *J*=8.2 Hz, 2H), 7.83 (d, *J*=8.2 Hz, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>, mixture of rotamers):  $\delta$  (major rotamer)=21.1 (CH<sub>2</sub>), 23.3 (CH<sub>3</sub>), 26.0 (CH<sub>2</sub>), 52.7 (CH<sub>2</sub>), 56.8 (CH<sub>3</sub>), 59.3 (CH<sub>3</sub>), 62.6 (CH), 74.0 (CH<sub>2</sub>), 114.3 (2× CH), 126.0 (C), 128.3 (2× CH), 158.4 (C), 165.0 (CO), 165.1 (CO) ppm. Anal. Calcd for C<sub>16</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>: C, 62.73; H, 7.24; N, 9.14%. Found: C, 62.96; H, 6.96; N, 8.97%.

#### **4.4.** Synthesis of enehydrazides (*S*)-3a–f. General procedure

A solution of KHMDS (0.5 M in toluene, 3 mL, 1.5 mmol) was added dropwise to a stirred solution of benzamide **8a,b** (1 mmol) and diphenyl chlorophosphate (0.31 mL, 1.5 mmol) in anhydrous THF (15 mL) at -78 °C under Ar. After stirring for 30 min at -78 °C, water (10 mL) was added and the mixture was extracted with Et<sub>2</sub>O (2×30 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated under vacuum to afford the intermediate vinyl phosphate **10a,b** as an oily product, which was then used in the coupling step without further purification.

Aqueous Na<sub>2</sub>CO<sub>3</sub> solution (2 M, 1 mL, 2 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (58 mg, 5 mol %) and aromatic boronic acid **11a**–**e** (1.5 mmol) were added under Ar to a stirred solution of crude **10a**,**b** (1 mmol) in THF (10 mL). The mixture was refluxed for 2 h, then diluted with water (10 mL) and extracted with Et<sub>2</sub>O ( $3 \times 15$  mL). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated under vacuum to give orange oil. Purification by flash column chromatography using EtOAc/hexanes (40:60) as eluent afforded enehydrazide (*S*)-**3a**–**f** as pale yellow oil.

4.4.1. *N*-((*S*)-2-*Methoxymethylpyrrolidin*-1-*yl*)-*N*-(1-*phenylvinyl*)benzamide [(*S*)-**3a**]. Pale yellow oil,  $[\alpha]_{D}^{2D}$  -115.7 (*c* 1.54, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2922, 1640, 1513 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.25-2.12 (m, 3H), 2.17-2.72 (m, 1H), 2.78-2.92 (m, 1H), 3.27 (s, 3H), 4.88 (br s, 1H), 5.12 (br s, 1H), 6.78-6.85 (m, 3H), 7.11-7.28 (m, 4H), 7.35-7.64 (m, 3H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.0 (CH<sub>2</sub>), 26.6 (CH<sub>2</sub>), 51.0 (CH<sub>2</sub>), 59.0 (CH<sub>3</sub>), 61.5 (CH), 75.4 (CH<sub>2</sub>), 115.4 (CH<sub>2</sub>), 127.5 (2× CH), 127.7 (2× CH), 128.0 (2× CH), 128.1 (2× CH), 127.8 (C), 127.9 (CH), 129.5 (C), 131.5 (CH), 147.3 (C), 171.8 (CO) ppm. Anal. Calcd for  $C_{21}H_{24}N_2O_2$ : C, 74.97; H, 7.19; N, 8.33%. Found: C, 74.79; H, 7.34; N, 8.12%.

4.4.2. *N*-[1-(3,4-Dimethoxyphenyl)vinyl]-*N*-((*S*)-2-methoxymethylpyrrolidin-1-yl)benzamide [(*S*)-**3b**]. Pale yellow oil,  $[\alpha]_D^{20}$  -110.0 (c 1.03, CHCl<sub>3</sub>). UV (MeOH, 10<sup>-4</sup> M)  $\lambda_{max}$ =205.8 ( $\epsilon$ =26×10<sup>3</sup>), 263.6 ( $\epsilon$ =9750), 297.6 ( $\epsilon$ =5200) nm. IR (neat)  $\nu$ =2928, 1651, 1514 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.22–2.12 (m, 3H), 2.19–2.68 (m, 1H), 3.24–3.65 (m, 5H), 3.22 (s, 3H), 3.47 (s, 3H), 3.55 (s, 3H), 4.96 (br s, 1H), 5.13 (br s, 1H), 6.65 (d, *J*=8.3 Hz, 1H), 7.11–7.33 (m, 5H), 7.87–7.95 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.1 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 51.8 (CH<sub>2</sub>), 55.6 (CH<sub>3</sub>), 55.7 (CH<sub>3</sub>), 58.7 (CH<sub>3</sub>), 61.7 (CH), 76.3 (CH<sub>2</sub>), 109.2 (CH<sub>2</sub>), 111.1 (CH), 111.9 (CH), 119.8 (CH), 128.0 (2× CH), 128.1 (C), 128.3 (CH), 130.2 (2× CH), 131.1 (C), 137.9 (C), 149.9 (C), 150.5 (C), 170.2 (CO) ppm. Anal. Calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>: C, 69.68; H, 7.12; N, 7.07%. Found: C, 69.72; H, 6.91; N, 7.20%.

4.4.3. *N*-((*S*)-2-*Methoxymethylpyrrolidin*-1-*y*l)-*N*-[1-(3,4,5-trimethoxyphenyl)vinyl]benzamide [(*S*)-**3***c*]. Pale yellow oil,  $[\alpha]_D^{20}$  –83.4 (c 1.27, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2930, 1651, 1518 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.20–2.07 (m, 3H), 2.15–2.68 (m, 1H), 2.74–2.91 (m, 1H), 3.12–3.60 (m, 4H), 3.21 (s, 3H), 3.47 (s, 3H), 3.55 (s, 3H), 5.05 (br s, 1H), 5.22 (br s, 1H), 6.68 (s, 2H), 7.10–7.40 (m, 3H), 7.47–7.71 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =21.3 (CH<sub>2</sub>), 26.0 (CH<sub>2</sub>), 51.3 (CH<sub>2</sub>), 55.3 (CH<sub>3</sub>), 55.8 (2× CH<sub>3</sub>), 58.9 (CH<sub>3</sub>), 61.4 (CH), 75.7 (CH<sub>2</sub>), 105.4 (2× CH), 109.4 (CH<sub>2</sub>), 127.7 (C), 128.2 (2× CH), 130.1 (2× CH), 130.8 (C), 132.8 (CH), 135.7 (C), 143.5 (C), 154.1 (2× C), 169.8 (CO) ppm. Anal. Calcd for C<sub>24</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>: C, 67.59; H, 7.09; N, 6.57%. Found: C, 67.37; H, 7.25; N, 6.62%.

4.4.4. *N*-((*S*)-2-*Methoxymethylpyrrolidin*-1-*y*l)-*N*-[1-(4-*methoxyphenyl)vinyl]benzamide* [(*S*)-**3d**]. Pale yellow oil,  $[\alpha]_{D}^{20}$  -113.8 (*c* 1.67, CHCl<sub>3</sub>). IR (neat) *v*=2926, 1654, 1508 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.22–2.12 (m, 3H), 2.18–2.56 (m, 1H), 3.00–3.38 (m, 2H), 3.19 (s, 3H), 3.37 (s, 3H), 3.42–3.64 (m, 1H), 3.66–3.92 (m, 1H), 4.31–4.60 (m, 1H), 4.89 (br s, 1H), 5.05 (br s, 1H), 6.84 (d, *J*=8.7 Hz, 2H), 6.98–7.21 (m, 3H), 7.54 (d, *J*=8.7 Hz, 2H), 7.81–7.97 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.2 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 51.6 (CH<sub>2</sub>), 55.1 (CH<sub>3</sub>), 58.7 (CH<sub>3</sub>), 61.5 (CH), 76.2 (CH<sub>2</sub>), 109.5 (CH<sub>2</sub>), 114.2 (2× CH), 127.8 (C), 128.0 (2× CH), 128.2 (2× CH), 128.3 (2× CH), 130.2 (CH), 130.7 (C), 137.8 (C), 160.4 (C), 170.1 (CO) ppm. Anal. Calcd for C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C, 72.11; H, 7.15; N, 7.64%. Found: C, 72.28; H, 7.04; N, 7.55%.

4.4.5. *N*-(1,1,3-*Benzodioxol-5-ylvinyl*)-*N*-((*S*)-2-methoxymethylpyrrolidin-1-yl)benzamide [(*S*)-**3***e*]. Pale yellow oil,  $[\alpha]_D^{20}$  –72.2 (*c* 1.64, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2930, 1650, 1515 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.51–2.04 (m, 3H), 2.21–2.59 (m, 1H), 3.04–3.34 (m, 2H), 3.19 (s, 3H), 3.39–3.94 (m, 2H), 4.15–4.58 (m, 1H), 4.81 (br s, 1H), 4.94 (br s, 1H), 5.33–5.37 (m, 2H), 6.70 (d, *J*=8.1 Hz, 1H), 7.01–7.14 (m, 3H), 7.22 (d, *J*=1.6 Hz, 1H), 7.27 (s, 1H), 7.82–7.93 (m, 2H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.2 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 51.6 (CH<sub>2</sub>), 58.7 (CH<sub>3</sub>), 61.3 (CH), 76.3 (CH<sub>2</sub>), 107.7 (CH), 108.3 (CH), 109.8 (CH<sub>2</sub>), 121.1 (CH), 127.9 (C), 128.0 (2× CH), 128.3 (CH), 130.2 (2× CH), 132.7 (C), 137.8 (C), 148.3 (C), 148.4 (C), 170.0 (CO) ppm. Anal. Calcd for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 69.46; H, 6.36; N, 7.36%. Found: C, 69.29; H, 6.18; N, 7.17%.

4.4.6. *N*-[1-(3,4-Dimethoxyphenyl)vinyl]-4-methoxy-*N*-((*S*)-2-methoxymethylpyrrolidin-1-yl)benzamide [(*S*)-**3***f*]. Pale yellow oil,  $[\alpha]_D^{20}$  -104.1 (*c* 1.22, CHCl<sub>3</sub>). IR (neat) *v*=2951, 1651, 1512 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CHCl<sub>3</sub>)  $\delta$ =1.17–1.98 (m, 3H), 2.18–2.56 (m, 1H), 3.10–3.22 (m, 1H), 3.20 (s, 3H), 3.24–3.43 (m, 1H), 3.39 (s, 3H), 3.48–3.91 (m, 3H), 3.55 (s, 3H), 3.62 (s, 3H), 4.94 (br s, 1H), 5.20 (br s, 1H), 6.63–6.74 (m, 3H), 7.14–7.27 (m, 2H), 7.89 (d, *J*=8.3 Hz,

2H) ppm. <sup>13</sup>C NMR (75 MHz, CHCl<sub>3</sub>):  $\delta$ =23.3 (CH<sub>2</sub>), 30.1 (CH<sub>2</sub>), 51.7 (CH<sub>2</sub>), 54.9 (CH<sub>3</sub>), 55.6 (CH<sub>3</sub>), 55.7 (CH<sub>3</sub>), 58.7 (CH<sub>3</sub>), 61.5 (CH), 76.3 (CH<sub>2</sub>), 109.5 (CH<sub>2</sub>), 111.1 (CH), 111.9 (CH), 113.3 (2× CH), 119.8 (CH), 128.1 (C), 129.7 (2× CH), 130.4 (C), 131.2 (C), 149.9 (C), 150.5 (C), 161.6 (C), 169.7 (CO) ppm. Anal. Calcd for C<sub>24</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>: C, 67.59; H, 7.09; N, 6.57%. Found: C, 67.76; H, 7.28; N, 6.75%.

# **4.5.** Photocyclization of enehydrazides (*S*)-3a–f. Synthesis of isoquinolinones (*S*,*S*)-4a–f. General procedure

Irradiations were performed in quartz vessel in a Rayonet RPR-208 photoreactor fitted with eight Rul 253.7 nm lamps. A solution of the enehydrazide (*S*)-**3a**–**f** (0.4 mmol) in MeOH (100 mL) was deareated by flushing it with Ar for 30 min. Deaeration and stirring of the solution were maintained during irradiation (4 h). Ar was freed of O<sub>2</sub> by passing it through a BTS catalyst and dried (P<sub>2</sub>O<sub>5</sub>). After irradiation the solvent was evaporated under vacuum and the residual photoproduct was purified by flash column chromatography using EtOAc/hexanes (20:80) as eluent. The solid isoquinolinones (*S*,*S*)-**4a**–**f** were finally recrystallized from hexane/ toluene.

4.5.1. (*S*)-2-((*S*)-2-Methoxymethylpyrrolidin-1-yl)-3-phenyl-3,4dihydro-2H-isoquinolin-1-one [(*S*,*S*)-**4a**]. Colorless crystals, mp 140–141 °C,  $[\alpha]_{D}^{20}$  –8.0 (*c* 0.71, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2934, 1652, 1494 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.64–2.07 (m, 3H), 2.62 (dd, *J*=2.2, 15.7 Hz, 2H), 2.67 (br s, 1H), 2.87 (t, *J*=8.8 Hz, 1H), 2.96 (s, 3H), 3.27–3.39 (m, 2H), 3.80 (br s, 1H), 4.31 (br s, 1H), 4.79 (dd, *J*=2.2, 7.0 Hz, 1H), 6.64 (d, *J*=7.5 Hz, 1H), 6.97–7.14 (m, 6H), 7.16 (t, *J*=7.5 Hz, 1H), 8.59 (dd, *J*=1.3, 7.7 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =24.0 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 37.1 (CH<sub>2</sub>), 52.4 (CH<sub>2</sub>), 58.4 (CH<sub>3</sub>), 61.3 (CH), 64.9 (CH), 76.1 (CH<sub>2</sub>), 127.0 (3× CH), 127.3 (CH), 127.6 (CH), 128.1 (CH), 128.5 (2× CH), 131.6 (C), 131.8 (CH), 135.4 (C), 142.5 (C), 162.9 (CO) ppm. Anal. Calcd for C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>: C, 74.97; H, 7.19; N, 8.33%. Found: C, 75.24; H, 7.33; N, 8.52%.

4.5.2. (S)-3-(3,4-Dimethoxyphenyl)-2-((S)-2-methoxymethylpyrrolidin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one [(S,S)-**4b**]. Colorless crystals, mp 85–86 °C,  $[\alpha]_D^{20}$  –8.6 (*c* 0.98, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2935, 1650, 1515 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.74–2.09 (m, 3H), 2.69 (dd, J=2.0, 15.6 Hz, 2H), 2.85 (br s, 1H), 2.98 (t, J=8.7 Hz, 1H), 3.01 (s, 3H), 3.29-3.48 (m, 2H), 3.38 (s, 3H), 3.43 (s, 3H), 3.87 (br s, 1H), 4.38 (br s, 1H), 4.80 (dd, J=1.8, 6.8 Hz, 1H), 6.42 (d, J=8.2 Hz, 1H), 6.64–6.75 (m, 3H), 7.10 (dt, *J*=1.6, 7.4 Hz, 1H), 7.18 (t, *J*=7.4 Hz, 1H), 8.63 (d, J=7.5 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz,  $C_6D_6$ ):  $\delta$ =24.0 (CH<sub>2</sub>), 28.6 (CH<sub>2</sub>), 37.4 (CH<sub>2</sub>), 52.5 (CH<sub>2</sub>), 55.4 (CH<sub>3</sub>), 55.5 (CH<sub>3</sub>), 58.5 (CH<sub>3</sub>), 61.4 (CH), 64.8 (CH), 76.3 (CH<sub>2</sub>), 110.9 (CH), 112.0 (CH), 119.2 (CH), 127.2 (CH), 127.5 (CH), 127.8 (CH), 131.7 (C), 131.8 (CH), 134.8 (C), 135.7 (C), 149.5 (C), 149.9 (C), 163.0 (CO) ppm. Anal. Calcd for C23H28N2O4: C, 69.68; H, 7.12; N, 7.07%. Found: C, 69.55; H, 6.85; N, 7.29%.

4.5.3. (*S*)-2-((*S*)-2-Methoxymethylpyrrolidin-1-yl)-3-(3,4,5-trimeth oxyphenyl)-3,4-dihydro-2H-isoquinolin-1-one [(*S*,*S*)-**4c**]. Colorless crystals, mp 98–99 °C,  $[\alpha]_D^{20}$  –7.6 (*c* 1.52, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2944, 1645, 1594 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.72–2.07 (m, 3H), 2.71 (d, *J*=15.3 Hz, 2H), 2.84 (br s, 1H), 2.98 (t, *J*=9.1 Hz, 1H), 3.00 (s, 3H), 3.32–3.43 (m, 2H), 3.42 (s, 6H), 3.83 (s, 3H), 3.87 (br s, 1H), 4.33 (br s, 1H), 4.77 (d, *J*=6.7 Hz, 1H), 6.39 (s, 2H), 6.73 (d, *J*=7.1 Hz, 1H), 7.09 (t, *J*=7.0 Hz, 1H), 7.17 (t, *J*=7.7 Hz, 1H), 8.58 (d, *J*=7.5 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =24.0 (CH<sub>2</sub>), 28.7 (CH<sub>2</sub>), 37.3 (CH<sub>2</sub>), 55.6 (2× CH<sub>3</sub>), 56.3 (CH<sub>3</sub>), 58.5 (CH<sub>3</sub>), 60.4 (CH), 64.7 (CH), 76.5 (CH<sub>2</sub>), 104.5 (2× CH), 127.3 (CH), 127.8 (CH), 127.9 (CH), 131.5 (C), 131.8 (CH), 135.6 (C), 137.7 (C), 145.5 (C), 154.0

4.5.4. (*S*)-2-((*S*)-2-Methoxymethylpyrrolidin-1-yl)-3-(4-methoxyphenyl)-3,4-dihydro-2H-isoquinolin-1-one [(*S*,*S*)-**4d**]. Colorless crystals, mp 114–115 °C,  $[\alpha]_{20}^{20}$  –6.3 (*c* 1.52, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2942, 1647, 1509 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.70–2.06 (m, 3H), 2.65 (dd, *J*=2.2, 15.7 Hz, 2H), 2.77 (br s, 1H), 2.93 (t, *J*=9.2 Hz, 1H), 3.00 (s, 3H), 3.23–3.42 (m, 2H), 3.29 (s, 3H), 3.81 (br s, 1H), 4.32 (br s, 1H), 4.78 (dd, *J*=2.1, 6.8 Hz, 1H), 6.63 (d, *J*=8.7 Hz, 2H), 6.71 (d, *J*=7.4 Hz, 1H), 7.01 (d, *J*=8.7 Hz, 2H), 7.11 (dt, *J*=1.5, 7.4 Hz, 1H), 7.19 (t, *J*=7.4 Hz, 1H), 8.62 (dd, *J*=1.3, 7.6 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.9 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 37.4 (CH<sub>2</sub>), 52.4 (CH<sub>2</sub>), 54.7 (CH<sub>3</sub>), 58.4 (CH<sub>3</sub>), 61.3 (CH), 64.4 (CH), 76.2 (CH<sub>2</sub>), 114.0 (2× CH), 127.2 (2× CH), 128.1 (CH), 128.2 (2× CH), 131.7 (C), 131.8 (CH), 134.4 (C), 135.7 (C), 159.5 (C), 163.0 (CO) ppm. Anal. Calcd for C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C, 72.11; H, 7.15; N, 7.64%. Found: C, 72.33; H, 7.31; N, 7.88%.

4.5.5. (*S*)-3,1,3-*Benzodioxol-5-yl-2-((S)-2-methoxymethylpyrrolidin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one* [(*S*,*S*)-**4e**]. Colorless crystals, mp 101–102 °C,  $[\alpha]_{D}^{20}$  –10.0 (*c* 1.32, CHCl<sub>3</sub>). IR (neat) *v*=2940, 1643, 1484 cm<sup>-1.</sup> <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ =1.70–2.05 (m, 3H), 2.60 (dd, *J*=2.5, 15.7 Hz, 2H), 2.91 (br s, 1H), 3.00 (t, *J*=8.5 Hz, 2H), 3.06 (s, 3H), 3.18–3.36 (m, 2H), 3.77 (br s, 1H), 4.32 (br s, 1H), 4.68 (dd, *J*=2.5, 6.8 Hz, 1H), 5.25 (d, *J*=1.2 Hz, 1H), 5.29 (d, *J*=1.2 Hz, 1H), 6.46–6.60 (m, 2H), 6.63–6.74 (m, 2H), 7.07 (dt, *J*=1.6, 7.4 Hz, 1H), 7.14 (t, *J*=7.3 Hz, 1H), 8.54 (dd, *J*=1.6, 7.3 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$ =23.9 (CH<sub>2</sub>), 28.5 (CH<sub>2</sub>), 37.3 (CH<sub>2</sub>), 52.3 (CH<sub>2</sub>), 58.5 (CH<sub>3</sub>), 61.3 (CH), 64.4 (CH), 76.3 (CH<sub>2</sub>), 101.0 (CH<sub>2</sub>), 107.6 (CH), 108.2 (CH), 120.4 (CH), 127.3 (CH), 128.2 (CH), 131.4 (C), 131.8 (CH), 135.5 (C), 136.4 (C), 147.4 (C), 148.1 (C), 163.0 (CO) ppm. Anal. Calcd for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 69.46; H, 6.36; N, 7.36%. Found: C, 69.22; H, 6.31; N, 7.44%.

4.5.6. (*S*)-3-(3,4-Dimethoxyphenyl)-6-methoxy-2-((*S*)-2-methoxy methylpyrrolidin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one [(*S*,*S*)-**4f**]. Colorless crystals, mp 118–119 °C,  $[\alpha]_{20}^{20}$  +26.8 (*c* 0.81, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2951, 1651, 1512 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =1.62–2.06 (m, 3H), 2.23 (br s, 1H), 2.72 (br s, 1H), 2.89 (dd, *J*=1.8, 15.7 Hz, 2H), 2.98 (s, 3H), 3.15–3.30 (m, 2H), 3.67–3.89 (m, 2H), 3.69 (s, 3H), 3.78 (s, 3H), 3.81 (s, 3H), 4.90 (d, *J*=6.2 Hz, 1H), 6.50 (d, *J*=2.3 Hz, 1H), 6.58 (d, *J*=1.8 Hz, 1H), 6.65 (dd, *J*=2.0, 8.3 Hz, 1H), 6.58 (d, *J*=2.3, 8.5 Hz, 1H), 8.04 (d, *J*=8.5 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =27.6 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>), 37.5 (CH<sub>2</sub>), 52.1 (CH<sub>2</sub>), 55.3 (CH<sub>3</sub>), 55.7 (CH<sub>3</sub>), 55.8 (CH<sub>3</sub>), 58.7 (CH<sub>3</sub>), 60.9 (CH), 64.9 (CH), 75.6 (CH<sub>2</sub>), 109.7 (CH), 110.8 (CH), 112.5 (CH), 112.8 (CH), 118.8 (CH), 123.4 (C), 129.5 (CH), 134.4 (C), 137.2 (C), 148.3 (C), 148.7 (C), 162.5 (C), 164.0 (CO) ppm. Anal. Calcd for C<sub>24</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>: C, 67.59; H, 7.09; N, 6.57%. Found: C, 67.35; H, 6.88; N, 6.79%.

# 4.6. Synthesis of (*S*)-3-aryl-3,4-dihydro-2*H*-isoquinolin-1-ones (*S*)-1a-f

Magnesium monoperoxyphthalate hexahydrate (MMPP) (247 mg, 0.5 mmol) was added to a solution of the isoquinolinone **4a**–**f** (0.2 mmol) in MeOH (5 mL), and the resulting mixture was then stirred at rt under argon for 2 h. The mixture was then poured in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and treated with a saturated NaHCO<sub>3</sub> solution (20 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×15 mL) and the combined extracts were washed successively with water (10 mL), brine (10 mL) and finally dried (MgSO<sub>4</sub>). After evaporation of the solvent the residue was purified by flash column chromatography using acetone/hexanes (30:70) as eluent to afford isoquinolinone (*S*)-**1a**–**f** as a solid, which was recrystallized from hexane/toluene.

4.6.1. (*S*)-3-*Phenyl*-3,4-*dihydro*-2*H*-*isoquinolin*-1-*one* [(*S*)-**1***a*]. Co lorless crystals, mp 130–131; lit.:<sup>5e</sup> mp 130–131 °C,  $[\alpha]_D^{20}$  –198.3 (*c* 0.97, CHCl<sub>3</sub>); lit.:<sup>5e</sup>  $[\alpha]_D^{20}$  –203.4 (*c* 1.03, CHCl<sub>3</sub>). Spectral data were identical to those already published.<sup>5e</sup>

4.6.2. (*S*)-3-(3,4-Dimethoxyphenyl)-3,4-dihydro-2H-isoquinolin-1one [(*S*)-**1b**]. Colorless crystals, mp 149–150; lit.:<sup>4a</sup> mp 149–150 °C,  $[\alpha]_D^{20}$  –102.8 (*c* 1.04, CHCl<sub>3</sub>); lit.:<sup>4a</sup> ee 72%  $[\alpha]_D^{20}$  –76.2 (*c* 0.28, MeOH). Spectral data were identical to those already published.<sup>4a</sup>

4.6.3. (*S*)-3-(3,4,5-Trimethoxyphenyl)-3,4-dihydro-2H-isoquinolin-1-one [(*S*)-**1***c*]. Colorless crystals, mp 97–98 °C,  $[\alpha]_{D}^{2D}$  –123.0 (*c* 0.96, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3171, 1655 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =3.05–3.26 (m, 2H), 3.86 (s, 9H), 4.79 (dd, *J*=5.0, 10.5 Hz, 1H), 6.29 (br s, 1H), 6.62 (s, 2H), 7.20 (d, *J*=7.4 Hz, 1H), 7.39 (t, *J*=7.3 Hz, 1H), 7.48 (d, *J*=1.4 Hz, 1H), 8.11 (d, *J*=7.6 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =37.7 (CH<sub>2</sub>), 56.2 (2× CH<sub>3</sub>), 56.5 (CH<sub>3</sub>), 60.9 (CH), 103.3 (2× CH), 127.3 (2× CH), 128.0 (CH), 128.2 (C), 132.6 (CH), 136.7 (C), 137.6 (C), 137.7 (C), 153.6 (C), 166.5 (CO) ppm. Anal. Calcd for C<sub>18</sub>H<sub>19</sub>NO<sub>4</sub>: C, 69.00; H, 6.11; N, 4.47%. Found: C, 69.18; H, 6.26; N, 4.29%.

4.6.4. (*S*)-3-(4-*Methoxyphenyl*)-3,4-*dihydro*-2*H*-isoquinolin-1-one [(*S*)-**1d**]. Colorless crystals, mp 91–92 °C,  $[\alpha]_D^{20}$  –163.6 (*c* 1.04, CHCl<sub>3</sub>). Spectral data were identical to those already published for a racemic sample.<sup>27</sup>

4.6.5. (*S*)-3,1,3-*Benzodioxol-5-yl-3,4-dihydro-2H-isoquinolin-1-one* [(*S*)-**1***e*]. Colorless crystals, mp 103–104 °C,  $[\alpha]_{D}^{20}$  –142.2 (*c* 1.10, CHCl<sub>3</sub>). IR (neat)  $\nu$ =3169, 1656 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =3.00–3.22 (m, 2H), 4.77 (dd, *J*=5.1, 10.5 Hz, 1H), 5.97 (s, 2H), 6.17 (br s, 1H), 6.76–6.90 (m, 3H), 7.18 (d, *J*=7.4 Hz, 1H), 7.37 (t, *J*=7.2 Hz, 1H), 7.46 (dt, *J*=1.3, 7.4 Hz, 1H), 8.10 (d, *J*=7.6 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =37.6 (CH<sub>2</sub>), 55.9 (CH), 101.3 (CH<sub>2</sub>), 106.8 (CH), 108.5 (CH), 120.1 (CH), 127.3 (CH), 127.4 (CH), 128.1 (CH), 128.3 (C), 132.5 (CH), 134.8 (C), 137.6 (C), 147.6 (C), 148.1 (C), 166.3 (CO) ppm. Anal. Calcd for C<sub>16</sub>H<sub>13</sub>NO<sub>3</sub>: C, 71.90; H, 4.90; N, 5.24%. Found: C, 71.87; H, 5.11; N, 5.00%.

4.6.6. (*S*)-3-(3,4-Dimethoxyphenyl)-6-methoxy-3,4-dihydro-2H-isoquinolin-1-one [(*S*)-**1***f*]. Colorless crystals, mp 118–119 °C,  $[\alpha]_{20}^{D0}$ –96.1 (*c* 1.12, CHCl<sub>3</sub>). IR (neat) *v*=3191, 1655 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =2.98–3.23 (m, 2H), 3.84 (s, 3H), 3.89 (s, 6H), 4.78 (dd, *J*=4.7, 11.3 Hz, 1H), 6.05 (br s, 1H), 6.67 (s, 1H), 6.81–6.98 (m, 4H), 8.05 (d, *J*=8.5 Hz, 1H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =38.0 (CH<sub>2</sub>), 55.4 (CH<sub>3</sub>), 56.0 (2× CH<sub>3</sub>), 109.2 (CH), 111.2 (CH), 112.5 (CH), 112.6 (CH), 118.8 (CH), 125.3 (C), 130.2 (CH), 133.6 (C), 139.9 (C), 148.9 (C), 149.3 (C), 162.9 (C+CO) ppm. Anal. Calcd for C<sub>18</sub>H<sub>19</sub>NO<sub>4</sub>: C, 69.00; H, 6.11; N, 4.47%. Found: C, 68.88; H, 5.94; N, 4.29%.

# **4.7.** Synthesis of (*S*)-3-aryl-1,2,3,4-tetrahydroisoquinolines (*S*)-2a,d,e

Boran/tetrahydrofuran complex (BH<sub>3</sub>·THF, 3.0 mL, 3.0 mmol, 1 M solution in THF) was added to an ice-cooled stirred solution of isoquinolinone **4a,d,e** (0.2 mmol) in dry THF (4 mL) under argon. The mixture was stirred at 0 °C for 1 h and then refluxed for 24 h. Aqueous 6 N HCl (2 mL) was added to the cooled reaction mixture and the resulting mixture was stirred at rt for 1 h and then refluxed for 1 h. The mixture was concentrated under vacuum, the residue was made basic with aqueous 2 N NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×10 mL). The combined organic layers were dried (MgSO<sub>4</sub>) and the solvent evaporated under vacuum. Purification by flash column chromatography using EtOAc/hexanes (90:10) as eluent.

4.7.1. (S)-3-Phenyl-1,2,3,4-tetrahydroisoquinoline [(S)-**2a**]. Pale yellow oil,  $[\alpha]_D^{20}$  –125.5 (c 0.48, CH<sub>2</sub>Cl<sub>2</sub>); lit.:<sup>24</sup> (R)-enantiomer  $[\alpha]_D^{20}$  +125.0 (c 0.55, CH<sub>2</sub>Cl<sub>2</sub>). Spectral data were identical to those already published.<sup>24</sup>

4.7.2. (S)-3-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline [(S)-**2d**]. Pale yellow oil,  $[\alpha]_D^{20}$  –118.8 (*c* 1.05, CHCl<sub>3</sub>); lit.:<sup>13</sup> (*R*)-enantiomer  $[\alpha]_D^{20}$  +119.1 (*c* 1.39, CHCl<sub>3</sub>). Spectral data were identical to those already published for the enantioenriched (ee 92%) (*R*)-**2d**.<sup>24</sup>

4.7.3. (*S*)-3,1,3-*Benzodioxol-5-yl-1,2,3,4-tetrahydroisoquinoline* [(*S*)-**2e**]. Pale yellow oil,  $[\alpha]_{\rm P}^{20}$  –115.5 (*c* 0.97, CHCl<sub>3</sub>). IR (neat)  $\nu$ =2897, 1485, 1434, 1230 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ =1.88 (br s, 1H), 2.90 (d, *J*=7.2 Hz, 2H), 3.90 (t, *J*=7.2 Hz, 1H), 4.12 (d, *J*=15.5 Hz, 1H), 4.22 (d, *J*=15.5 Hz, 1H), 5.91 (s, 2H), 6.78 (d, *J*=8.0 Hz, 1H), 6.87 (dd, *J*=1.5, 8.0 Hz, 1H), 6.94 (d, *J*=1.5 Hz, 1H), 7.01–7.18 (m, 4H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ =37.9 (CH<sub>2</sub>), 49.3 (CH<sub>2</sub>), 58.4 (CH), 101.0 (CH<sub>2</sub>), 107.1 (CH), 108.2 (CH), 119.7 (CH), 125.9 (CH), 126.2 (CH), 126.3 (CH), 129.1 (CH), 134.9 (C), 135.0 (C), 138.5 (C), 146.7 (C), 147.8 (C) ppm. Anal. Calcd for C<sub>16</sub>H<sub>15</sub>NO<sub>2</sub>: C, 75.87; H, 5.97; N, 5.53%. Found: C, 76.04; H, 6.12; N, 5.77%.

#### Acknowledgements

This research was supported by the CNRS and by MENESR.

#### **References and notes**

- (a) Bentley, K. W. Nat. Prod. Rep. 2003, 20, 342–365; (b) Scott, J. D.; Williams, R. M. Chem. Rev. 2002, 102, 1669–1730; (c) Bentley, K. W. Nat. Prod. Rep. 2001, 18, 148–170; (d) Lezama, E. J.; Konkar, A. A.; Salazar-Bookaman, M. M.; Miller, D. D.; Feller, D. R. Eur, J. Pharmacol. 1996, 308, 69–80; (e) Minor, D. L.; Wyrick, S. D.; Charifson, P. S.; Watts, V. J.; Nichols, D. E.; Mailman, R. B. J. Med. Chem. 1994, 37, 4317–4328; (f) Hanaoka, M. Transformation Reactions of Protoberberines Alkaloids. In; Brossi, A., Ed.; The Alkaloids; Academic: New York, NY, 1988; Vol. 33, pp 141–230; (g) Herbert, R. B. In The Chemistry and Biology of Isoquinoline Alkaloids; Phillipson, J. D., Roberts, M. F., Zenk, M. H., Eds.; Springer: Berlin, 1985; pp 213–228; (h) Dyke, S. F.; Kinsman, R. G. In; Grethe, G., Ed.; Chemistry of Heterocyclic Compounds: Isoquinolines, Part 1; Wiley: New York, NY, 1981; Vol 38, pp 1–137; (i) Shamma, M.; Moniot, J. L. Isoquinoline Alkaloid Research 1972–1977; Plenum: New York, NY, 1978; (j) Kametani, T. The Chemistry of the Isoquinoline Alkaloids; Elsevier: Amsterdam, 1969.
- 2. Charifson, P. S. Drugs Future 1989, 14, 1179-1185.
- (a) Maruyama, W.; Naoi, M.; Kasamatsu, T.; Hashizume, Y.; Takahashi, T.; Kohda, K.; Dostert, P. J. Neurochem. **1997**, 69, 322–329; (b) Tatton, W. G.; Ju, W. Y. L.; Holland, D. P.; Tai, C.; Kwan, M. J. Neurochem. **1994**, 63, 1572–1575.
- (a) Grajewska, A.; Rozwadowska, M. D. Tetrahedron: Asymmetry 2007, 18, 2910–2914;
   (b) Chrzanowska, M.; Dreas, A.; Rozwadowska, M. D. Tetrahedron: Asymmetry 2005, 16, 2910–2914;
   (c) Liu, L. Synthesis 2003, 1705–1706;
   (d) Vicario, J. L.; Badia, D.; Carrillo, L.; Anakabe, E. Tetrahedron: Asymmetry 2003, 14, 347–353.
- (a) Derdau, V.; Snieckus, V. J. Org. Chem. 2001, 66, 1992-1998; (b) Davis, F. A.; Mohanty, P. K.; Burns, D. M.; Andemichael, Y. W. Org. Lett. 2000, 2, 3901-3903; (c) Brozda, D.; Koroniak, L.; Rozwadowska, M. D. Tetrahedron: Asymmetry 2000, 11, 3017-3025; (d) Hanessian, S.; Demont, E.; van Otterlo, W. A. L. Tetrahedron Lett. 2000, 41, 4999-5003; (e) Davis, F. A.; Andemichael, Y. W. J. Org. Chem. 1999, 64, 8627-8634; (f) Vicario, J. L.; Badia, D.; Dominguez, E.; Carrillo, L. J. Org. Chem. 1999, 64, 4610-4616; (g) Carrillo, L.; Badia, D.; Dominguez, E.; Anakabe, E.; Osante, I.; Tellitu, I.; Vicario, J. L. J. Org. Chem. 1999, 64, 1115-1120; (h) Katritzky, A. R.; Cobo-Domingo, J.; Yang, B.; Steel, P. J. Tetrahedron: Asymmetry 1999, 10, 255-263; (i) Ohba, M.; Nishimura, Y.; Kato, M.; Fujii, T. Tetrahedron 1999, 55, 4999-5016; (j) Barbier, D.; Marazano, C.; Riche, C.; Das, B. C.; Potier, P. J. Org. Chem. 1998, 63, 1767-1772; (k) Monsees, A.; Laschat, S.; Dix, I.; Jones, P. G. J. Org. Chem. 1998, 63, 10018-10021; (1) Davis, F. A.; Andemichael, Y. W. Tetrahedron Lett. 1998, 39, 3099-3102; (m) Gosmann, G.; Guillaume, D.; Husson, H.-P. Tetrahedron Lett. 1996, 37, 4369-4372; (n) Tellitu, I.; Badia, D.; Dominguez, E.; Garcia, F. J. Tetrahedron: Asymmetry 1994, 5, 1567-1578.
- (a) Chrzanowska, M.; Rozwadowska, M. D. Chem. Rev. 2004, 104, 3341–3370;
   (b) Morimoto, T.; Suzuki, N.; Achiwa, K. Tetrahedron: Asymmetry 1998, 9, 183–187;
   (c) Venkov, A. P.; Ivanov, I. I. Tetrahedron 1996, 52, 12299–12308;
   (d)

Corey, E. J.; Gin, D. Y. *Tetrahedron Lett.* **1996**, *37*, 7163–7166; (e) Cox, E. D.; Cook, J. M. *Chem. Rev.* **1995**, *95*, 1797–1842; (f) Larsen, R. D.; Reamer, R. A.; Corley, E. G.; Davis, P.; Grabowski, E. J. J.; Reider, P. J.; Shinkai, I. *J. Org. Chem.* **1991**, *56*, 6034–6038.

- (a) Vicario, J. L.; Badia, D.; Dominguez, E.; Carrillo, L. Tetrahedron: Asymmetry 2000, 11, 1227–1237; (b) Vicario, J. L.; Badia, D.; Dominguez, E.; Crespo, A.; Carrillo, L. Tetrahedron: Asymmetry 1999, 10, 1947–1959; (c) Ishikawa, T.; Ishii, H. Heterocycles 1999, 50, 627–639; (d) Carrillo, L.; Badia, D.; Dominguez, E.; Vicario, J. L.; Tellitu, I. J. Org. Chem. 1997, 62, 6716–6721; (e) Meyers, A. I. Tetrahedron 1992, 48, 2589–2612; (f) Gözler, B. In; Brossi, A., Ed.; The Alkaloids; Academic: San Diego, 1987; Vol. 31, pp 317–388; (g) Bhakuni, D. S.; Jain, S. In; Brossi, A., Ed.; The Alkaloids; Academic: Orlando, 1986; Vol. 28, pp 95–181; (h) Santavy, F. In; Manske, R. H. F., Rodrigo, R. G. A., Eds.; The Alkaloids; Academic: New York, NY, 1979; Vol. 17, pp 385–544.
- (a) Valenta, V.; Holubek, J.; Svatek, E.; Dlabac, A.; Bartosova, M.; Protiva, M. Collect. Czech. Chem. Commun. **1983**, 48, 1447–1464; (b) Cushman, M.; Choong, T. C.; Valko, J. T.; Koleck, M. P. J. Org. Chem. **1980**, 45, 5067–5073; (c) Shamma, M.; Tomlinson, H. H. J. Org. Chem. **1978**, 43, 2852–2855; (d) Ito, K.; Furukawa, H.; Iida, T.; Lee, K.-H.; Soine, T. O. J. Chem. Soc., Chem. Commun. **1974**, 1037–1038; (e) Kametani, T.; Hirata, S.; Ogasawara, K. J. Chem. Soc., Perkin Trans. 1 **1973**, 1466–1470.
- Hisamichi, H.; Shimada, I.; Ishihara, T.; Takuwa, T.; Shimizu, T.; Ishikawa, N.; Maeno, K.; Seki, N. PCT Int. Appl., WO 2008146774, 2008; *Chem. Abstr.* 2008, 150, 20012.
- Rothweiler, U.; Czarna, A.; Krajewski, M.; Ciombor, J.; Kalinski, C.; Khazak, V.; Ross, G.; Skobeleva, N.; Weber, L.; Holak, T. A. *ChemMedChem* **2008**, 3, 1118–1128.
- (a) Clark, R. D.; Jahangir, A. Org. React. 1995, 47, 1–314; (b) Snieckus, V. Chem. Rev. 1990, 90, 879–933; (c) Clark, R. D.; Jahangir, A. J. Org. Chem. 1989, 54, 1174–1178; (d) Jahangir, A.; Fisher, L. E.; Clark, R. D.; Muchowski, J. M. J. Org. Chem. 1989, 54, 2992–2996; (e) Clark, R. D.; Jahangir, A. J. Org. Chem. 1988, 53, 2378–2381; (f) Clark, R. D.; Jahangir, A. J. Org. Chem. 1987, 52, 5378–5382.
   (a) Davis, F. A.; Chao, B.; Andemichael, Y. W.; Mohanty, P. K.; Fang, T.; Burns, D.
- (a) Davis, F. A.; Chao, B.; Andemichael, Y. W.; Mohanty, P. K.; Fang, T.; Burns, D. M.; Rao, A.; Szewczyk, J. M. *Heteroat. Chem.* **2002**, *13*, 486–492; (b) Davis, F. A.; Mohanty, P. K. J. Org. Chem. **2002**, *67*, 1290–1296.
- 13. Enders, D.; Braig, V.; Boudou, M.; Raabe, G. Synthesis 2004, 2980–2990.
- (a) Griesbeck, A. G. In; Ma, S., Ed.; Handbook of Cyclization; Wiley: Weinheim, 2010; Vol. 2, pp 1149–1197; (b) Grese, T. A.; Adrian, M. D.; Phillips, D. L.; Shetler, P. K.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 2001, 44, 2857–2860; (c) Rigby, J. H.; Gupta, V. Synlett 1995, 547–548; (d) Couture, A.; Grandclaudon, P.; Hooijer, S. O. J. Org. Chem. 1991, 56, 4977–4980; (e) Kametani, T.; Sugai, T.; Shoji, Y.; Honda, T.; Satoh, F.; Fukumoto, K. J. Chem. Soc., Perkin Trans. 1 1977, 1151–1155; (f) Ninomiya, I.; Shinohara, A.; Kiguchi, T.; Naito, T. J. Chem. Soc., Perkin Trans. 1 1976, 1868–1872; (g) Lenz, G. R. J. Org. Chem. 1976, 41, 2201–2207.
- 15. Inoue, Y. Chem. Rev. 1992, 92, 741-770.
- (a) Naito, T.; Katsumi, K.; Tada, Y.; Ninomiya, I. *Heterocycles* 1983, 20, 779–782;
  (b) Naito, T.; Tada, Y.; Ninomiya, I. *Heterocycles* 1981, 16, 1141–1143.
- (a) Hjelmgaard, T.; Gardette, D.; Tanner, D.; Aitken, D. J. *Tetrahedron: Asymmetry* 2007, *18*, 671–678; (b) Bois, F.; Gardette, D.; Gramain, J.-C. *Tetrahedron Lett.* 2000, *41*, 8769–8772.
- Kametani, T.; Takagi, N.; Toyota, M.; Honda, T.; Fukumoto, K. J. Chem. Soc., Perkin Trans. 1 1981, 2830–2834.
- Tracey, M. R.; Hsung, R. P.; Antoline, J.; Kurtz, K. C. M.; Shen, L.; Slafer, B. W.; Zhang, Y. Sci. Synth. 2005, 21, 387–475.
- 20. Takai, K.; Oshima, K.; Nozaki, H. Tetrahedron Lett. 1980, 21, 2531–2534.
- (a) Bouet, A.; Cieslikiewicz, M.; Lewinski, K.; Coudert, G.; Gillaizeau, I. *Tetrahedron* **2010**, 66, 498–503; (b) Steel, P. G.; Woods, T. M. Synthesis **2009**, 3897–3904; (c) Fuwa, H.; Sasaki, M. Org. Lett. **2007**, *9*, 3347–3350; (d) Hansen, A. L.; Ebran, J.-P.; Gogsig, T. M.; Skrydstrup, T.J. Org. Chem. **2007**, 72, 6464–6472; (e) Claveau, E.; Gillaizeau, I.; Blu, J.; Bruel, A.; Coudert, G. J. Org. Chem. **2007**, 72, 4832–4836; (f) Occhiato, E. G.; Lo Galbo, F.; Guarna, A. J. Org. Chem. **2005**, 70, 7324–7330; (g) Lepifre, F.; Clavier, S.; Bouyssou, P.; Coudert, G. *Tetrahedron* **2001**, *57*, 6969–6975.
- 22. No trace of the (*S*,*R*) diastereoisomer could be detected in the crude photoreaction mixture.
- Hayashi, R.; Walton, M. C.; Hsung, R. P.; Schwab, J. H.; Yu, X. Org. Lett. 2010, 12, 5768–5771.
- (a) Dumoulin, D.; Lebrun, S.; Deniau, D.; Couture, A.; Grandclaudon, P. Eur. J. Org. Chem. 2009, 3741–3752; (b) Fernández, R.; Ferrete, A.; Llera, J. M.; Magriz, A.; Martín-Zamora, E.; Díez, E.; Lassaletta, J. M. Chem.—Eur. J. 2004, 10, 737–745; (c) Fernández, R.; Ferrete, A.; Lassaletta, J. M.; Llera, J. M.; Martín-Zamora, E. Angew. Chem., Int. Ed. 2002, 41, 831–833.
- 25. Garcia, D.; Foubelo, F.; Yus, M. Eur. J. Org. Chem. 2010, 2893-2903.
- 26. Deniau, E.; Couture, A.; Grandclaudon, P. Tetrahedron: Asymmetry 2008, 19, 2735–2740.
- 27. Rakshit, S.; Grohmann, C.; Besset, T.; Glorius, F. J. Am. Chem. Soc. 2011, 133, 2350–2353.